I 
109TH CONGRESS 
2D SESSION 
H. R. 5836 
To amend the Public Health Service Act with respect to making progress 
toward the goal of eliminating tuberculosis, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JULY 19, 2006 
Mr. BROWN of Ohio (for himself and Mrs. WILSON of New Mexico) introduced 
the following bill; which was referred to the Committee on Energy and 
Commerce 
A BILL 
To amend the Public Health Service Act with respect to 
making progress toward the goal of eliminating tuber-
culosis, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
(a) SHORT TITLE.—This Act may be cited as the 
‘‘Comprehensive Tuberculosis Elimination Act of 2006’’. 
(b) TABLE OF CONTENTS.—The table of contents for 
this Act is as follows: 
Sec. 1. Short title; table of contents. 
Sec. 2. Findings. 
TITLE I—CENTERS FOR DISEASE CONTROL AND PREVENTION 
VerDate Aug 31 2005 
00:37 Jul 21, 2006
Jkt 049200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6211
E:\BILLS\H5836.IH
H5836
ycherry on PROD1PC64 with BILLS
Subtitle A—National Program for Elimination of Tuberculosis 
Sec. 101. National program. 
Subtitle B—Interagency Collaboration 
Sec. 111. Advisory council for elimination of tuberculosis. 
Subtitle C—New Tools for Tuberculosis Elimination 
Sec. 121. New tools. 
Subtitle D—Authorizations of Appropriations 
Sec. 131. Authorizations of appropriations. 
TITLE II—NATIONAL INSTITUTES OF HEALTH 
Sec. 201. Activities of National Heart, Lung, and Blood Institute. 
Sec. 202. Activities of National institute of Allergy and Infectious Diseases. 
Sec. 203. John E. Fogarty International Center for Advanced Study in the 
Health Sciences. 
Sec. 204. Loan repayment programs regarding research on tuberculosis. 
SEC. 2. FINDINGS. 
The Congress finds as follows: 
(1) Each year approximately 9 million people 
become ill with active tuberculosis (‘‘TB’’) and 2 
million of those people die. This is a direct result of 
the disease having the ability to develop resistance 
to treatments and to travel easily across borders. 
(2) In 2005, there were 14,093 cases of active 
TB reported in the United States. However, the de-
cline of 3.8 percent in the national TB case rate 
from 2004 to 2005 was one of the smallest declines 
in more than a decade. 
(3) In addition to those with active TB, an esti-
mated 10 to 15 million people in the United States 
have latent TB. 
VerDate Aug 31 2005 
00:37 Jul 21, 2006
Jkt 049200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H5836.IH
H5836
ycherry on PROD1PC64 with BILLS
(4) The increasing occurrence of multidrug re-
sistant TB, including extensively drug-resistant 
TB—which is resistant to at least two main first- 
line drugs and additionally to three or more of the 
six classes of second-line drugs—raises concerns of 
a future epidemic of virtually untreatable TB. 
(5) New tools are needed to more effectively 
prevent, diagnose, and treat TB. The standard 
method of diagnosing TB is over 100 years old, and 
fails to adequately detect TB in children and those 
coinfected with HIV/AIDS. The newest class of anti- 
TB drug is 40 years old, while rates of multidrug 
resistant TB are rising globally. 
TITLE I—CENTERS FOR DISEASE 
CONTROL AND PREVENTION 
Subtitle A—National Program for 
Elimination of Tuberculosis 
SEC. 101. NATIONAL PROGRAM. 
Section 317E of the Public Health Service Act (42 
U.S.C. 247b-6) is amended— 
(1) by striking the heading for the section and 
inserting the following: ‘‘NATIONAL
PROGRAM 
FOR ELIMINATION OF TUBERCULOSIS’’; and 
(2) by amending subsection (b) to read as fol-
lows: 
VerDate Aug 31 2005 
00:37 Jul 21, 2006
Jkt 049200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H5836.IH
H5836
ycherry on PROD1PC64 with BILLS
‘‘(b) RESEARCH AND DEVELOPMENT; DEMONSTRA-
TION PROJECTS; EDUCATION AND TRAINING.—With re-
spect to the prevention, control and elimination of tuber-
culosis, the Secretary may, directly or through grants to 
public or nonprofit private entities, carry out the following: 
‘‘(1) Research, with priority given to research 
and development concerning— 
‘‘(A) clinical trials to evaluate the safety 
and effectiveness of new drugs, diagnostics, and 
vaccines for latent tuberculosis infection and ac-
tive tuberculosis; 
‘‘(B) epidemiological studies of populations 
at risk of tuberculosis; and 
‘‘(C) field studies to evaluate the effective-
ness of new drugs, diagnostics, and vaccines, 
and evaluation of efforts to eliminate the dis-
ease. 
‘‘(2) Demonstration projects for— 
‘‘(A) the development of regional capabili-
ties to prevent, control and eliminate tuber-
culosis; 
‘‘(B) the intensification of efforts to pre-
vent, detect, and treat tuberculosis among Afri-
can Americans and reduce or eliminate the ra-
VerDate Aug 31 2005 
00:37 Jul 21, 2006
Jkt 049200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H5836.IH
H5836
ycherry on PROD1PC64 with BILLS
cial disparity in the incidence of tuberculosis in 
that population; 
‘‘(C) the intensification of efforts to con-
trol tuberculosis along the United States-Mexico 
border and among United States-Mexico bina-
tional populations; 
‘‘(D) the intensification of efforts to pre-
vent, detect, and treat tuberculosis among for-
eign-born persons who are in the United States; 
and 
‘‘(E) collaboration with Immigration and 
Customs Enforcement to identify and treat im-
migrants with active or latent tuberculosis in-
fection. 
‘‘(3) A public information and education pro-
gram. 
‘‘(4) Education, training and clinical skills im-
provement activities for health professionals, includ-
ing allied health personnel and emergency response 
employees. 
‘‘(5) Provide support for the Tuberculosis 
Trials Consortium, the Tuberculosis Epidemiologic 
Studies Consortium, and Regional Training and 
Medical Consultation Centers to carry out activities 
under paragraphs (1) through (4). 
VerDate Aug 31 2005 
00:37 Jul 21, 2006
Jkt 049200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H5836.IH
H5836
ycherry on PROD1PC64 with BILLS